BRIM II trial established the effective, nontoxic dose of Vemurafenib to be 960 mg taken twice a day. When taken orally, the medication reaches its peak concentration in plasma within 3 hours. The half-life ranges between 30-120 hours and achieves a plasma steady state within 15 to 22 days. The medication is started twice daily with a 12-hour interval between the two doses and should be stopped if there is a progression of melanoma or high-grade toxicity.